Literatur
-
1
Levine J A, Lanningham-Foster L M, McCrady S K. et al .
Interindividual variation in posture allocation: possible role in human obesity.
Science.
2005;
307
584-586
-
2
Wadden T A, Berkowitz R I, Womble L G. et al .
Randomized trial of lifestyle modification and pharmacotherapy for obesity.
N Engl J Med.
2005;
353
2111-2120
-
3
Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O. RIO-Europe Study Group .
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Lancet.
2005;
365
1389-1397
-
4
Pi-Sunyer F X, Aronne L J, Heshmati H M, Devin J, Rosenstock J,. RIO-North America Study Group .
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America.
JAMA.
2006;
295
761-775
, ; Erratum in: JAMA. 2006 Mar 15;295:1252.
-
5
Donnez J, Dolmans M M, Demylle D. et al .
Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.
Lancet.
2004;
364
1405-1410
-
6
Silber S J, Lenahan K M, Levine D J. et al .
Ovarian transplantation between monozygotic twins discordant for premature ovarian failure.
N Engl J Med.
2005;
353
58-63
-
7
Alexander E K, Marqusee E, Lawrence J. et al. .
Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism.
N Engl J Med.
2004;
351
241-249
-
8
Centanni M, Gargano L, Canettieri G. et al .
Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis.
N Engl J Med.
2006;
354
1787-1795
-
9
Ayuk J, Clayton R N, Holder G. et al. .
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
J Clin Endocrinol Metab.
2004;
89
1613-1617
-
10
Feenstra J, de Herder W W, ten Have S M. et al .
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
Lancet.
2005;
365
1644-1646
-
11
Valkema R, Pauwels S. et al .
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Semin Nucl Med.
2006;
36
147-156
-
12
Kwekkeboom D J, Teunissen J J, Bakker W H. et al .
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
J Clin Oncol.
2005;
23
54-62
Prof. Dr. Martin Reincke
Medizinische Klinik - Innenstadt Klinikum der LMU München
Ziemssenstraße 1
80336 München
Telefon: +49/89/51602100
Fax: +49/89/51604428
eMail: martin.reincke@med.uni-muenchen.de
